Pharmacology of Insulin

1. Introduction/Overview

Insulin represents a cornerstone of pharmacotherapy for diabetes mellitus, a metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The discovery of insulin in 1921 by Banting, Best, Collip, and Macleod transformed type 1 diabetes from a universally fatal disease into a manageable chronic condition. As a polypeptide hormone, insulin’s primary physiological role is the regulation of carbohydrate, fat, and protein metabolism. Its pharmacological administration is essential for survival in type 1 diabetes and is a critical component of treatment for many individuals with type 2 diabetes, particularly as beta-cell function declines over time. The clinical relevance of insulin pharmacology extends beyond diabetes to conditions such as hyperkalemia and, in specialized settings, anabolic support.

The importance of understanding insulin pharmacology cannot be overstated for healthcare professionals. Mastery of its pharmacokinetic profiles, mechanisms, and adverse effect profiles is required for safe and effective therapeutic application. This chapter provides a systematic examination of insulin as a drug, from its molecular mechanisms to its clinical use in diverse patient populations.

Learning Objectives

• Describe the structural classification of insulin preparations, including human insulins and analog insulins, based on their pharmacokinetic properties.
• Explain the molecular mechanism of action of insulin, including receptor binding, signal transduction pathways, and resultant metabolic effects on glucose, lipid, and protein metabolism.
• Compare and contrast the absorption, distribution, metabolism, and excretion (ADME) characteristics of rapid-acting, short-acting, intermediate-acting, and long-acting insulin formulations.
• Identify the approved therapeutic indications for insulin therapy, including specific applications in type 1 and type 2 diabetes mellitus, gestational diabetes, and hyperkalemia.
• Analyze the major adverse effects associated with insulin therapy, particularly hypoglycemia and weight gain, and develop strategies for their prevention and management.

2. Classification

Insulin preparations are classified primarily according to their source and pharmacokinetic profile, specifically their onset, peak, and duration of action. This classification is fundamental to constructing physiologically rational replacement regimens.

Classification by Source and Structure

Historically, insulin was derived from bovine or porcine pancreata. These animal-sourced insulins differ slightly in amino acid sequence from human insulin, which could lead to immunogenicity. Contemporary therapy predominantly uses insulin that is identical in sequence to endogenous human insulin, produced via recombinant DNA technology using Escherichia coli or Saccharomyces cerevisiae. A more advanced category is the insulin analogs, which are structurally modified human insulins engineered to alter pharmacokinetic properties. Modifications typically involve amino acid substitutions in the B-chain or the addition of fatty acid side chains, which affect self-association, subcutaneous absorption, and receptor binding affinity.

Classification by Pharmacokinetic Profile

This functional classification is most clinically relevant for therapeutic regimen design.

• Rapid-Acting Insulin Analogs: These include insulin lispro, insulin aspart, and insulin glulisine. Amino acid sequence modifications reduce the propensity for hexamer formation after subcutaneous injection, leading to rapid dissociation into monomers and swift absorption. They are typically administered immediately before or after meals to control postprandial glucose excursions.
• Short-Acting (Regular) Insulin: Human regular insulin exists as a hexamer in solution, which must dissociate into dimers and monomers before absorption, resulting in a slower onset. It is administered 30-45 minutes before a meal.
• Intermediate-Acting Insulin: Neutral Protamine Hagedorn (NPH) insulin is a suspension of insulin complexed with the protein protamine, which delays absorption. It provides basal insulin coverage for approximately 12-18 hours.
• Long-Acting Insulin Analogs: This class includes insulin glargine, insulin detemir, and insulin degludec. Modifications such as pH-dependent precipitation (glargine), albumin binding (detemir), or multi-hexamer formation with slow dissociation (degludec) create a slow, steady, and prolonged absorption profile with minimal peak activity, mimicking physiological basal insulin secretion.
• Ultra-Long-Acting Insulin Analogs: Insulin degludec and the more concentrated insulin glargine U-300 are characterized by durations of action exceeding 24 hours, often up to 42 hours for degludec, providing very stable basal coverage.
• Premixed Insulins: These are fixed-ratio combinations, typically of a rapid- or short-acting insulin with an intermediate-acting insulin (e.g., 70/30 NPH/regular, 75/25 lispro protamine/lispro). They offer convenience but less flexibility in dose titration.

3. Mechanism of Action

The mechanism of insulin action is a complex cascade of events beginning with receptor binding and culminating in widespread metabolic and growth-promoting effects.

Receptor Interactions

Insulin exerts its effects by binding to the insulin receptor, a transmembrane glycoprotein of the receptor tyrosine kinase family. The receptor is a heterotetramer consisting of two extracellular α-subunits that contain the insulin-binding domain and two transmembrane β-subunits that possess intrinsic tyrosine kinase activity. Insulin binding induces a conformational change in the α-subunits, which brings the β-subunits into close proximity, facilitating trans-autophosphorylation of specific tyrosine residues on the intracellular domains. This activation of the receptor’s tyrosine kinase is the initial critical step in signal transduction.

Molecular and Cellular Mechanisms

Following receptor autophosphorylation, the activated receptor phosphorylates several intracellular docking proteins, most notably the insulin receptor substrates (IRS-1 through IRS-4). Tyrosine-phosphorylated IRS proteins then serve as docking sites for proteins containing Src homology 2 (SH2) domains, initiating two principal signaling pathways:

1. The PI3-Kinase/Akt Pathway: This is the primary pathway for metabolic actions. Phosphoinositide 3-kinase (PI3K) is recruited and activated, leading to the generation of phosphatidylinositol (3,4,5)-trisphosphate (PIP₃) at the plasma membrane. PIP₃ recruits phosphoinositide-dependent kinase-1 (PDK1) and Akt (protein kinase B). Akt, once activated by phosphorylation, mediates most of insulin’s metabolic effects:
   • Glucose Transport: Akt activation stimulates the translocation of glucose transporter type 4 (GLUT4) vesicles from intracellular stores to the plasma membrane in muscle and adipose tissue, dramatically increasing the rate of facilitated diffusion of glucose into cells.
   • Glycogen Synthesis: Akt phosphorylates and inhibits glycogen synthase kinase-3 (GSK-3), relieving its inhibition of glycogen synthase, thereby promoting glycogen storage.
   • Protein Synthesis: The Akt/mTOR pathway stimulates ribosomal protein synthesis and inhibits protein degradation.
   • Lipid Metabolism: Akt promotes lipid synthesis (lipogenesis) by activating key enzymes and inhibits lipolysis by phosphorylating and inhibiting hormone-sensitive lipase.
2. The MAP Kinase Pathway: Activation of the Ras/Raf/MEK/ERK cascade by insulin is more associated with its mitogenic and growth-promoting effects, such as DNA synthesis and cell proliferation.

Integrated Pharmacodynamic Effects

The culmination of these signaling events results in the characteristic anabolic and anticatabolic state promoted by insulin:

• Carbohydrate Metabolism: Insulin lowers blood glucose by increasing cellular glucose uptake (especially in muscle and fat), enhancing glycolysis, and promoting glycogenesis in the liver and muscle. It simultaneously suppresses hepatic glucose production (gluconeogenesis and glycogenolysis).
• Lipid Metabolism: Insulin promotes fatty acid and triglyceride synthesis in the liver (lipogenesis) and inhibits the breakdown of stored triglycerides in adipose tissue (lipolysis), reducing the release of free fatty acids and glycerol into the circulation.
• Protein Metabolism: Insulin stimulates amino acid uptake into cells, increases the rate of protein synthesis, and decreases protein degradation, resulting in a positive nitrogen balance.
• Potassium Homeostasis: Insulin stimulates the activity of the Na⁺/K⁺-ATPase pump, promoting the intracellular movement of potassium. This effect is independent of its glucose-lowering action and is the basis for its use in treating hyperkalemia.

4. Pharmacokinetics

The pharmacokinetics of insulin are predominantly characterized by its absorption from subcutaneous tissue, as it is almost always administered via subcutaneous injection. Intravenous administration is reserved for specific inpatient scenarios.

Absorption

Subcutaneous absorption is the rate-limiting step for all insulin formulations and is influenced by multiple factors. Insulin molecules must traverse the capillary endothelium to enter the systemic circulation. The rate of absorption is determined by the formulation’s propensity to self-associate:

• Rapid-acting analogs (lispro, aspart, glulisine) are designed to remain as monomers or dimers in solution, leading to very rapid absorption with an onset of action within 10-20 minutes, a peak at 30-90 minutes, and a duration of 3-5 hours.
• Short-acting (Regular) insulin forms hexamers that must dissociate, resulting in an onset of 30-60 minutes, a peak at 2-3 hours, and a duration of 5-8 hours.
• Intermediate-acting (NPH) insulin exists as a crystalline suspension complexed with protamine. The crystals must dissolve at the injection site, leading to a delayed onset (1-2 hours), a broad peak (4-10 hours), and a duration of 10-18 hours.
• Long-acting analogs employ various strategies to prolong absorption. Insulin glargine is formulated at an acidic pH and precipitates in the neutral subcutaneous tissue, forming a depot from which insulin slowly dissolves. Insulin detemir binds to albumin via its fatty acid side chain, delaying distribution. Insulin degludec forms multi-hexamers that dissociate extremely slowly. These agents have onsets of 1-2 hours, minimal peak effects, and durations ranging from 18-24 hours (detemir, glargine U-100) to beyond 24 hours (degludec, glargine U-300).

Factors affecting subcutaneous absorption include injection site (abdomen > arm > thigh > buttock), depth of injection, local blood flow (increased by heat, massage, or exercise), and lipohypertrophy at repeated injection sites.

Distribution

Following absorption into the bloodstream, insulin distributes into a volume roughly equivalent to the extracellular fluid. It does not cross the blood-brain barrier to a significant degree under normal physiological conditions. Insulin detemir is highly bound (>98%) to albumin in the plasma, which contributes to its prolonged action.

Metabolism and Excretion

Endogenous insulin is cleared primarily by the liver (via receptor-mediated endocytosis and degradation) and the kidneys. Approximately 50-60% of insulin secreted into the portal vein is extracted and degraded by the liver in a first-pass effect before reaching the systemic circulation. Pharmacologically administered subcutaneous insulin enters the systemic circulation directly, bypassing first-pass hepatic metabolism. The kidneys become a more significant route of clearance, filtering insulin at the glomerulus and degrading it in the proximal tubules. The metabolic clearance rate of insulin is rapid, with a plasma half-life of approximately 4-6 minutes when administered intravenously. However, the subcutaneous absorption rate governs the overall pharmacokinetic profile, making the apparent half-life much longer. In renal or hepatic impairment, insulin clearance is reduced, increasing the risk of accumulation and hypoglycemia, necessitating dose reduction.

Half-life and Dosing Considerations

The terminal half-life (t_1/2) following subcutaneous administration varies by formulation: rapid-acting analogs (~1 hour), regular insulin (~1.5 hours), NPH insulin (~2-4 hours), and long-acting analogs (5-25 hours, depending on the analog). Dosing regimens are constructed to mimic physiological insulin secretion, which consists of a continuous basal level with superimposed prandial (meal-time) bursts. A common regimen involves a once- or twice-daily long-acting analog for basal needs and a rapid-acting analog before each meal for prandial coverage. The dose is highly individualized, based on body weight, insulin sensitivity, carbohydrate intake, and physical activity levels. A typical total daily dose (TDD) initiation in type 1 diabetes may be 0.4-0.5 units/kg/day, with approximately 40-50% provided as basal insulin and the remainder as prandial insulin.

5. Therapeutic Uses/Clinical Applications

Insulin therapy is indicated for a spectrum of conditions centered on the correction of insulin deficiency or the overcoming of significant insulin resistance.

Approved Indications

• Type 1 Diabetes Mellitus: Insulin is an absolute requirement for survival, as autoimmune destruction of pancreatic beta-cells results in an absolute deficiency of endogenous insulin. Lifelong, multiple daily injection therapy or continuous subcutaneous insulin infusion (insulin pump therapy) is necessary.
• Type 2 Diabetes Mellitus: Insulin is indicated when glycemic targets are not achieved with non-insulin antihyperglycemic agents (e.g., metformin, SGLT2 inhibitors, GLP-1 receptor agonists), often as beta-cell function declines. It may be initiated as add-on therapy or as a standalone agent. It is also used during periods of acute illness, surgery, or hospitalization where glycemic control is critical.
• Gestational Diabetes Mellitus (GDM): When medical nutrition therapy fails to achieve glycemic goals in GDM, insulin is the preferred pharmacologic agent due to its efficacy and lack of placental transfer, making it safe for the fetus.
• Hyperkalemia: Intravenous administration of insulin (typically 10 units of regular insulin with 25-50g of glucose to prevent hypoglycemia) is a standard emergency treatment for severe hyperkalemia. It works by stimulating cellular uptake of potassium via the Na⁺/K⁺-ATPase pump.
• Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS): Continuous intravenous infusion of regular insulin is the standard of care for these acute, life-threatening complications of diabetes, aimed at reversing ketosis, correcting acidosis, and gradually lowering plasma glucose.

Off-Label and Specialized Uses

Insulin is sometimes used in specialized parenteral nutrition protocols to promote anabolism and improve nitrogen balance in critically ill or severely malnourished patients. Its use in type 2 diabetes is sometimes combined with a GLP-1 receptor agonist in a single injection device (e.g., insulin degludec/liraglutide) to leverage complementary mechanisms of action. In the research setting, insulin is a component of hyperinsulinemic-euglycemic clamps, the gold-standard method for measuring insulin sensitivity.

6. Adverse Effects

While life-saving, insulin therapy is associated with several significant adverse effects, the most serious of which is hypoglycemia.

Common Side Effects

• Hypoglycemia: This is the most frequent and dangerous acute complication. Symptoms are categorized as autonomic (tremor, palpitations, sweating, hunger) and neuroglycopenic (confusion, drowsiness, speech difficulty, seizures, coma). Severe hypoglycemia, requiring assistance from another person, carries significant morbidity and mortality risk. Risk factors include excessive dose, delayed or missed meals, unplanned physical activity, alcohol consumption, and renal impairment.
• Weight Gain: Insulin promotes lipogenesis and inhibits lipolysis, leading to increased fat storage. Weight gain is a common consequence of initiating or intensifying insulin therapy, which can exacerbate insulin resistance and create a psychological barrier to treatment.
• Injection Site Reactions: Localized lipohypertrophy (accumulation of fat tissue) or lipoatrophy (loss of fat tissue) can occur with repeated injections in the same area. Lipoatrophy is now rare with human and analog insulins. Pain, redness, or itching may also occur.

Serious and Rare Adverse Reactions

• Severe Hypoglycemia: Can lead to loss of consciousness, seizures, neurological damage, cardiac arrhythmias, and death.
• Hypokalemia: Particularly a risk during treatment of DKA or hyperkalemia, as insulin drives potassium intracellularly.
• Systemic Allergic Reactions: True immunoglobulin E (IgE)-mediated anaphylaxis to modern recombinant human insulins is exceedingly rare but has been reported.
• Peripheral Edema: Insulin has mild antinatriuretic effects and can cause sodium and water retention, leading to edema, particularly when glycemic control is rapidly improved after a period of chronic hyperglycemia (“insulin edema”).
• Refractive Errors: Rapid changes in plasma glucose can alter the osmolarity of the lens, causing transient blurring of vision.

Warnings

All insulin products carry a boxed warning regarding the risk of hypoglycemia. This warning emphasizes that insulin is a potent drug requiring careful dosing, monitoring, and patient education. Dosing errors between different insulin concentrations (e.g., U-100 vs. U-500) have resulted in severe hypoglycemia and death, warranting extreme caution.

7. Drug Interactions

Numerous drugs can influence glycemic control and thus interact with insulin therapy, either potentiating or antagonizing its hypoglycemic effect.

Major Drug-Drug Interactions

• Drugs that Potentiate Hypoglycemic Effect (Increase Risk of Hypoglycemia):
  • Other Antidiabetic Agents: Concurrent use with sulfonylureas, meglitinides, or GLP-1 receptor agonists increases hypoglycemia risk.
  • Beta-Adrenergic Blockers: Non-selective beta-blockers (e.g., propranolol) can mask the autonomic warning symptoms of hypoglycemia (tachycardia, tremor) and may impair counter-regulatory hormonal responses.
  • Angiotensin-Converting Enzyme (ACE) Inhibitors: May improve insulin sensitivity and potentially increase hypoglycemia risk.
  • Salicylates (High Dose): Have hypoglycemic properties.
  • Monoamine Oxidase Inhibitors (MAOIs), Pentamidine, Quinine/Quinidine: Can cause hypoglycemia.
  • Anabolic Steroids, Androgens: May increase insulin sensitivity.
• Drugs that Antagonize Hypoglycemic Effect (Increase Insulin Requirements/Hyperglycemia):
  • Corticosteroids: Potent inducers of insulin resistance and increased hepatic glucose production.
  • Thiazide and Loop Diuretics: Can cause hyperglycemia, possibly via hypokalemia-induced impairment of insulin secretion.
  • Sympathomimetic Agents: Epinephrine, albuterol, and other beta-2 agonists stimulate glycogenolysis and gluconeogenesis.
  • Atypical Antipsychotics (e.g., olanzapine, clozapine): Associated with weight gain and insulin resistance.
  • Protease Inhibitors, Niacin, Phenytoin, Thyroid Hormones: Can elevate blood glucose.

Contraindications

The only absolute contraindication to insulin therapy is hypersensitivity to insulin itself or to an excipient in a specific formulation, which is exceptionally rare. Insulin must be used with extreme caution, and doses must be meticulously adjusted, during episodes of hypoglycemia. Relative contraindications exist for specific situations; for example, the use of certain long-acting analogs in patients with a history of frequent, severe hypoglycemia may require careful selection of an agent with a less pronounced peak (if using NPH) or a more stable profile.

8. Special Considerations

Insulin therapy requires careful adjustment in specific patient populations due to altered pharmacokinetics, pharmacodynamics, or safety profiles.

Pregnancy and Lactation

Insulin is the drug of choice for the management of diabetes during pregnancy (preexisting type 1/2 or GDM) as it does not cross the placenta in significant amounts. Human insulin and insulin analogs (with the exception of insulin glargine, for which large prospective safety data are limited) are considered safe. Requirements often decrease in the first trimester due to nausea, increase significantly in the second and third trimesters due to placental hormone-induced insulin resistance, and drop precipitously after delivery. During lactation, insulin requirements are typically lower than pre-pregnancy levels. Insulin is considered compatible with breastfeeding as it is a large peptide not excreted into breast milk in clinically relevant amounts.

Pediatric Considerations

Dosing in children is based on body weight and is highly variable, often requiring higher doses per kilogram than adults due to growth hormone effects and varying activity levels. Careful education of both the child and caregivers regarding carbohydrate counting, injection technique, and hypoglycemia recognition/treatment is paramount. Insulin pump therapy is commonly used in pediatric populations to improve flexibility and control.

Geriatric Considerations

Older adults are at increased risk for hypoglycemia due to blunted counter-regulatory hormone responses, polypharmacy, renal impairment, and sometimes erratic eating patterns. Glycemic targets are often relaxed (e.g., HbA1c < 8.0-8.5%) to minimize hypoglycemia risk. Long-acting analogs with minimal peak activity and lower risk of nocturnal hypoglycemia may be preferred. Simplified regimens may also be considered to improve adherence.

Renal Impairment

The kidney is a major site of insulin clearance. As renal function declines, insulin degradation decreases, leading to prolonged half-life and increased risk of hypoglycemia. Dose reductions of 25-50% are often necessary when the glomerular filtration rate (GFR) falls below 50 mL/min/1.73m², with more substantial reductions required in end-stage renal disease. Careful monitoring is essential.

Hepatic Impairment

The liver is responsible for a significant portion of insulin metabolism. In severe liver disease (e.g., cirrhosis), insulin clearance is reduced, and peripheral insulin resistance is often present due to portosystemic shunting and other factors. The net effect on insulin requirements is unpredictable; some patients may require lower doses due to reduced clearance, while others may require higher doses due to profound insulin resistance. Frequent blood glucose monitoring is required to guide therapy.

9. Summary/Key Points

• Insulin is a polypeptide hormone essential for the regulation of carbohydrate, lipid, and protein metabolism. Its pharmacological replacement is life-saving in type 1 diabetes and a critical therapy in advanced type 2 diabetes.
• Insulin preparations are classified by pharmacokinetic profile: rapid-acting analogs (lispro, aspart, glulisine), short-acting (regular), intermediate-acting (NPH), and long-acting analogs (glargine, detemir, degludec). This classification guides regimen design to mimic physiological basal-bolus secretion.
• The mechanism of action involves binding to the transmembrane insulin receptor, activating intrinsic tyrosine kinase activity, and initiating signaling cascades (primarily PI3K/Akt) that stimulate GLUT4 translocation, glycogen synthesis, lipogenesis, and protein synthesis while inhibiting gluconeogenesis and lipolysis.
• Pharmacokinetics are dominated by subcutaneous absorption kinetics. Rapid-acting analogs have a quick onset and short duration for prandial coverage, while long-acting analogs provide a steady, peakless basal coverage for up to 42 hours. Insulin is metabolized primarily by the liver and kidneys.
• The primary therapeutic indications are type 1 and type 2 diabetes mellitus, gestational diabetes, and the emergency treatment of hyperkalemia and diabetic ketoacidosis.
• The most significant adverse effect is hypoglycemia, which can be severe and life-threatening. Weight gain and injection site reactions are also common.
• Many drugs interact with insulin; corticosteroids and beta-agonists can raise blood glucose, while beta-blockers, ACE inhibitors, and other antidiabetics can increase hypoglycemia risk.
• Special considerations are required in pregnancy (insulin is drug of choice), pediatrics, geriatrics, and patients with renal or hepatic impairment, often necessitating dose adjustments and modified glycemic targets.

Clinical Pearls

• “Stacking” insulin doses—administering an additional dose of rapid-acting insulin before the previous dose has fully dissipated—is a common cause of unexpected hypoglycemia.
• When correcting hyperglycemia with a supplemental (“correction”) dose of insulin, the insulin sensitivity factor (ISF), or how much one unit of insulin lowers blood glucose, must be considered alongside the carbohydrate-to-insulin ratio (CIR) for meal dosing.
• In patients with renal impairment, long-acting insulin analogs with stable pharmacokinetics (e.g., degludec, glargine U-300) may offer a lower risk of hypoglycemia compared to NPH insulin.
• The “dawn phenomenon” (early morning rise in blood glucose due to growth hormone surge) must be distinguished from the “Somogyi effect” (rebound hyperglycemia following nocturnal hypoglycemia) to guide appropriate bedtime insulin adjustments.
• Continuous glucose monitoring (CGM) systems have revolutionized insulin therapy by providing real-time glucose trends and alerts for impending hypoglycemia, enabling more precise and safer dose titration.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.